Bradanicline is a potent and highly selective agonist of the α7 nicotinic acetylcholine receptor (nAChR) with an EC50 of 17 nM and a Ki of 1.4 nM for the human α7 nAChR. It is primarily employed in research pertaining to cognitive disorders [1] [2].
Anatoxin-a (ATX-a), a neurotoxic alkaloid, functions as an agonist for the nicotinic acetylcholine receptor (nAChR) and as an inhibitor of Acetylcholinesterase (AChE) [1] [2].